AU2001293209A1 - Nitrogenous heterocyclic compounds - Google Patents

Nitrogenous heterocyclic compounds

Info

Publication number
AU2001293209A1
AU2001293209A1 AU2001293209A AU9320901A AU2001293209A1 AU 2001293209 A1 AU2001293209 A1 AU 2001293209A1 AU 2001293209 A AU2001293209 A AU 2001293209A AU 9320901 A AU9320901 A AU 9320901A AU 2001293209 A1 AU2001293209 A1 AU 2001293209A1
Authority
AU
Australia
Prior art keywords
kinases
heterocyclic compounds
phosphorylation
pharmaceutically acceptable
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293209A
Inventor
Shigeki Fujiwara
Michio Ichimura
Shinichi Ide
Junko Irie
Kenji Matsuno
Yuji Nomoto
Shoji Oda
Anjali Pandey
Robert M. Scarborough Jr.
Eiji Tsukuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
COR Therapeutics Inc
Original Assignee
Kyowa Hakko Kogyo Co Ltd
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, COR Therapeutics Inc filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of AU2001293209A1 publication Critical patent/AU2001293209A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
AU2001293209A 2000-08-18 2001-08-17 Nitrogenous heterocyclic compounds Abandoned AU2001293209A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22608900P 2000-08-18 2000-08-18
US60226089 2000-08-18
PCT/US2001/041751 WO2002016362A2 (en) 2000-08-18 2001-08-17 Nitrogenous heterocyclic compounds

Publications (1)

Publication Number Publication Date
AU2001293209A1 true AU2001293209A1 (en) 2002-03-04

Family

ID=22847506

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001293209A Abandoned AU2001293209A1 (en) 2000-08-18 2001-08-17 Nitrogenous heterocyclic compounds

Country Status (8)

Country Link
US (2) US6956039B2 (en)
EP (1) EP1309569B1 (en)
AT (1) ATE483693T1 (en)
AU (1) AU2001293209A1 (en)
DE (1) DE60143204D1 (en)
DK (1) DK1309569T3 (en)
ES (1) ES2354039T3 (en)
WO (1) WO2002016362A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE483693T1 (en) * 2000-08-18 2010-10-15 Millennium Pharm Inc N-ARYL-Ä4-Ä7-(ALKOXY)QUINAZOLINE-4-YLÜPIPERAZINYLÜCARBOXAMIDE COMPOUNDS AS PDGF RECEPTOR INHIBITORS
EP1309568B1 (en) 2000-08-18 2011-02-16 Millennium Pharmaceuticals, Inc. [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor
PT1315715E (en) 2000-08-18 2008-10-30 Millennium Pharm Inc Quinazoline derivatives as kinase inhibitors
AU2002217999A1 (en) * 2000-11-01 2002-05-15 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
AU2002254152A1 (en) 2001-03-08 2002-09-24 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US20100179162A1 (en) * 2005-07-20 2010-07-15 Millennium Pharmaceuticals , Inc. Crystal forms of 4-[6-methoxy-7(3-piperidin-1-yl-propoxy) quinazoline-4yl) piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide
CA2643044A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
CA2696021C (en) 2006-08-11 2015-09-29 Nicolas Winssinger Macrocyclic compounds useful as inhibitors of kinases and hsp90
EP2370417A2 (en) * 2008-11-21 2011-10-05 Millennium Pharmaceuticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882717B1 (en) 1996-10-01 2010-09-08 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
AU3053999A (en) 1998-03-31 1999-10-25 Kyowa Hakko Kogyo Co. Ltd. Nitrogenous heterocyclic compounds
AU2001293207A1 (en) 2000-08-18 2002-03-04 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
ATE483693T1 (en) * 2000-08-18 2010-10-15 Millennium Pharm Inc N-ARYL-Ä4-Ä7-(ALKOXY)QUINAZOLINE-4-YLÜPIPERAZINYLÜCARBOXAMIDE COMPOUNDS AS PDGF RECEPTOR INHIBITORS
EP1309568B1 (en) 2000-08-18 2011-02-16 Millennium Pharmaceuticals, Inc. [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor
PT1315715E (en) 2000-08-18 2008-10-30 Millennium Pharm Inc Quinazoline derivatives as kinase inhibitors
AU2002254152A1 (en) 2001-03-08 2002-09-24 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases

Also Published As

Publication number Publication date
DE60143204D1 (en) 2010-11-18
US6956039B2 (en) 2005-10-18
DK1309569T3 (en) 2011-01-24
ATE483693T1 (en) 2010-10-15
WO2002016362A3 (en) 2002-06-13
US20040186110A1 (en) 2004-09-23
EP1309569B1 (en) 2010-10-06
US20060063770A1 (en) 2006-03-23
WO2002016362A2 (en) 2002-02-28
EP1309569A2 (en) 2003-05-14
ES2354039T3 (en) 2011-03-09

Similar Documents

Publication Publication Date Title
EP1964839A3 (en) Quinazoline derivatives as kinase inhibitors
WO2002072578A3 (en) (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
WO2002016360A3 (en) Nitrogenous heterocyclic compounds
AU2001293209A1 (en) Nitrogenous heterocyclic compounds
MY134848A (en) Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
CA2509650A1 (en) C-6 modified indazolylpyrrolotriazines
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
MY145634A (en) Pyrrolotriazine compounds as kinase inhibitors
EA200701504A1 (en) INDOLS SUITABLE FOR THE TREATMENT OF INFLAMMATION
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
WO2008005956A3 (en) Pyrrolotriazine kinase inhibitors
WO2000043373A3 (en) Kinase inhibitors
CA2400447A1 (en) Kinase inhibitors
WO2000055159A3 (en) Substituted aza-oxindole derivatives
AU2001293208A1 (en) Nitrogenous heterocyclic compounds
RU2007116863A (en) APPLICATION OF RENIN FOR PREVENTION OR TREATMENT OF DIASTOLIC DYSFUNCTION OR DIASTOLIC HEART FAILURE
NO983992L (en) Serine protease inhibitors
WO2001012579A3 (en) New stilbenes with vascular damaging activity
AU2002217999A1 (en) Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
NO20055518L (en) 5-hydroxyindoles with N-oxide groups, use thereof as phosphodiesterase 4 inhibitor
WO2002094768A3 (en) Aza hydroxylated ethyl amine compounds
AU2002362008A1 (en) Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease